This database contains 370 studies, archived under the term: "treatment outcome"
Click here to filter this large number of results.
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer’s disease (AD).; Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory […]
A randomized controlled pilot study to evaluate a technology platform for the assisted living of people with dementia and their carers
Torkamani, Mariam,
McDonald, Louise,
Saez Aguayo, Ignasi,
Kanios, Christos,
Katsanou, Maria-Nefeli,
Madeley, Laura,
Limousin, Patricia D.,
Lees, Andrew J.,
Haritou, Maria,
Jahanshahi, Marjan
The use of telemedicine is becoming increasingly popular in assisting with the home management of People with Dementia (PwD) by offering services to the carers that may enhance their ability to care for their relative for longer. A computerized platform, ALADDIN, was evaluated in its usefulness to reduce carer burden and distress and to improve […]
The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington’s disease: a pilot study
Thompson, J. A.,
Cruickshank, T. M.,
Penailillo, L. E.,
Lee, J. W.,
Newton, R. U.,
Barker, R. A.,
Ziman, M. R.
Background and Purpose: Despite advances in the understanding of Huntington’s disease (HD), treatment remains symptomatic. Multidisciplinary rehabilitation, however, appears to impact disease progression. Here we show the feasibility, safety and efficacy of a 9-month multidisciplinary rehabilitation programme in a small cohort of patients with early-to-middle-stage HD.; Methods: Twenty patients with HD were assigned to two […]
Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial
Teranishi, Mika,
Kurita, Masatake,
Nishino, Satoshi,
Takeyoshi, Kenji,
Numata, Yukio,
Sato, Tadahiro,
Tateno, Amane,
Okubo, Yoshiro
The descriptive term behavioral and psychological symptoms of dementia (BPSD) is used to cover a range of noncognitive disturbances including anxiety, depression, irritability, aggression, agitation, eating disorders, and inappropriate social or sexual behaviors. Behavioral and psychological symptoms of dementia are seen in about 90% of patients with dementia. We aimed to compare the efficacy and […]
The Montreal Cognitive Assessment (MoCA) in geriatric rehabilitation: psychometric properties and association with rehabilitation outcomes
Sweet, Lisa,
Van Adel, Mike,
Metcalf, Valerie,
Wright, Lisa,
Harley, Anne,
Leiva, René,
Taler, Vanessa
Background: Cognitive status has been reported to be an important predictor of rehabilitation outcome. The Montreal Cognitive Assessment (MoCA) was designed to overcome some of the limitations of established cognitive screening tools such as the Mini-Mental State Examination (MMSE). The purpose of this study is to evaluate the psychometric characteristics of the MoCA as a […]
The peaceful mind program: a pilot test of a cognitive-behavioral therapy-based intervention for anxious patients with dementia
Stanley, Melinda A.,
Calleo, Jessica,
Bush, Amber L.,
Wilson, Nancy,
Snow, A. Lynn,
Kraus-Schuman, Cynthia,
Paukert, Amber L.,
Petersen, Nancy J.,
Brenes, Gretchen A.,
Schulz, Paul E.,
Williams, Susan P.,
Kunik, Mark E.
Objectives: To assess feasibility and to conduct a preliminary evaluation of outcomes following Peaceful Mind, a cognitive-behavioral therapy-based intervention for anxiety in dementia, relative to usual care.; Design: Pilot randomized controlled trial including assessments at baseline and 3 and 6 months.; Setting: Houston, TX.; Participants: Thirty-two outpatients diagnosed with mild (47%) or moderate (53%) dementia […]
Cognitive subdomain responses to galantamine in Alzheimer’s disease
Song, Jihye,
Ahn, Inn Sook,
Kang, Hyo Shin,
Myung, Woojae,
Lee, Yujin,
Woo, Sook-young,
Ku, Hyoung Mo,
Hwang, Tae-Young,
Carroll, Bernard J.,
Kim, Doh Kwan
We investigated the effects of galantamine on cognitive subdomains in Alzheimer’s disease (AD). Sixty-six patients with mild-to-moderate AD received open-label galantamine for 52 weeks. Cognitive function was measured using the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog-K). Response to galantamine was defined as “improvement or no deterioration” on the total scores of […]
Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep
Many patients with Alzheimer’s disease experience sleep disturbances, and donepezil is usually prescribed for night-time administration. However, increased acetylcholine is associated with cortical arousal. We evaluated whether subjective sleep quality differed according to the timing of medication administration. Ninety-two patients with mild to moderate Alzheimer’s disease who had taken donepezil at night (n=54) or galantamine […]